Written By | Business Experts
According to the officials, the proposed draft would have granted the U.S. government extensive, unilateral access to Namibians' medical information. "
Search
Windhoek
Namibia has told the United States that proposed agreements on sharing Namibians' health data and biological specimens are, in their current form, incompatible with Namibian law — a refusal that leaves roughly US$45 million in projected 2027 funding for the country's HIV programs unresolved with the American budget cycle closing in weeks.
Government officials told The Namibian that the objections were raised after a proposal to fund mostly HIV and tuberculosis programs, worth more than N$145 million a year, was put through legal scrutiny by the Office of the Attorney General. "The Namibian government has made it unequivocally clear that the data-sharing or specimen-sharing agreements in their proposed forms are not in compliance with Namibia's national laws," officials said.
The stance places Namibia among a small group of African states that have declined the health deals Washington has offered across the continent since December 2025, and it does so at the moment of maximum leverage for the other side: the U.S. budget appropriation falls at the end of next month.
What the draft agreement asked for
According to the officials, the proposed draft would have granted the U.S. government extensive, unilateral access to Namibians' medical information. "This aspired access, however, infringes upon the constitutional right to privacy and national sovereignty over biological resources," they said.
They further argued that the negotiations, which involved the Attorney General's office, would have contravened Namibia's Access to Biological and Genetic Resources and Associated Knowledge Act and the Public and Environmental Health Act by bypassing mandatory requirements for export permits, prior informed consent and equitable benefit-sharing.
Namibia's objections produced one partial concession. In November 2025, the U.S. government confirmed it would withdraw the biological specimen-sharing agreement from the funding negotiations. The wider question of health data, however, remains on the table. "Negotiations on a broader agreement progressed slowly because matters related to the data-sharing agreement needed to be discussed in detail and resolved," officials said.
Washington disputes the characterization. A U.S. government source told The Namibian last week that the negotiations did not involve sharing personally identifiable data and that there appeared to be a misunderstanding of the proposed agreement, saying the U.S. would collect only aggregate data and that a sentence in the draft states explicitly that Namibia would not share personally identifiable information. U.S. embassy spokesperson Ryan Bradeen said the two governments were still discussing the future of health assistance: "We are unable to provide a response at the moment because of the timing of the request. It is a critical moment at which the Namibian and U.S. governments are still discussing future health assistance." The embassy did not respond to a further request on Sunday.
The money at stake
Should no agreement be reached, the Ministry of Health says Namibia will need to find about N$730 million to sustain its HIV/AIDS programs. "The potential impact is significant if an agreement is not reached on mutually acceptable terms. The amount for 2027 is about US$45 million (N$730 million)," officials said, adding that Namibia "has actively explored contingency funding mechanisms and alternative resources to ensure sustainability and continuity in the provision of essential care and to guard against reversals of the gains that Namibia has made against HIV-AIDS."
That last clause is the crux. Namibia is one of southern Africa's better-performing HIV responses, built over two decades with heavy American support: the U.S. President's Emergency Plan for AIDS Relief has contributed more than US$1.1 billion for HIV/AIDS activities in Namibia since its inception in 2003. Losing a portion of that at short notice is survivable on a spreadsheet; losing continuity of antiretroviral supply is not.
A continental pattern
Namibia's decision is not happening in isolation. Since President Donald Trump's return to office, his administration has dismantled the U.S. Agency for International Development — officially closed in July 2025 — and replaced its architecture with the America First Global Health Strategy, which bypasses non-governmental implementers and routes money directly to African and Latin American governments.
Secretary of State Marco Rubio set out the logic in the 2025 strategy document. "Moving forward, we will use our foreign health assistance to advance U.S. priorities and move countries towards resilient and durable local health systems," he wrote, adding: "We will also partner with each country to ensure there are data systems in place that can both monitor potential outbreaks and broader health outcomes."
The scale of the resulting deal-making is substantial. African Business reported in July that since December 2025 the U.S. government has signed memorandums of understanding worth around $20.6 billion with more than 30 countries worldwide, typically exchanging five years of funding for commitments to provide up to 25 years of patient data and disease pathogens. Twenty-one African countries have signed under the strategy, the magazine reported, including Nigeria, the Democratic Republic of Congo, Ethiopia and Uganda. The Guardian reported in February that up to 20 African countries had signed up, and that the rapid push was seen as part of U.S. maneuvers to establish and entrench power on the continent; it also reported that the deals commit African nations to rely on U.S. regulatory approval of new drugs and technologies before rolling them out, and that the U.S.-Rwanda deal is explicit that it will bring increased U.S. private-sector involvement in that country's health sector.
Washington's stated rationale is pandemic self-protection: having left the World Health Organization in January, it no longer receives outbreak data and pathogen samples through that channel.
Resistance has been growing. Ghana, South Africa, Zambia and Zimbabwe have all rejected the deals or paused talks over data privacy and sovereignty concerns. Ayoade Alakija, a Nigerian ministerial health envoy and co-chair of the African Vaccine Delivery Alliance, has called the arrangement "a recolonisation of our health system." Nick Mangwana, permanent secretary in Zimbabwe's information ministry, explained Harare's withdrawal in terms of reciprocity: "Zimbabwe was being asked to share its biological resources and data over an extended period, with no corresponding guarantee of access to any medical innovations — such as vaccines, diagnostics, or treatments — that might result from that shared data," he said. "In essence, our nation would provide the raw materials for scientific discovery without any assurance that the end products would be accessible to our people should a future health crisis emerge."
Kenya offers the cautionary legal precedent. Nairobi signed a data-sharing agreement in December 2025 that included U.S. commitments of around $1.6 billion over five years. Within days, Kenya's High Court issued an interim order halting implementation after a petition by the Consumers Federation of Kenya, which argued the public had never been consulted and that the deal breached data-protection statutes and the constitutional right to privacy. Kenya's Court of Appeal lifted those restrictions in May 2026, with a full ruling expected by October.
The domestic politics
Inside Namibia, the issue has been driven partly by parliamentary pressure. Lilani Brinkman, a member of parliament for the Independent Patriots for Change and the opposition's shadow health minister, questioned Health Minister Esperance Luvindao in March about whether Namibia had been approached over new bilateral health funding and whether any discussions involved sharing health data, surveillance information or biological materials. She asked that parliament be fully informed. The ministry has not provided a formal response.
"We are a sovereign country, and the health data of Namibians cannot be treated as a bargaining tool for donor assistance," Brinkman told The Namibian last week, adding that the government must stop relying on donors for health funding.
Notably, the government's position has support across party lines. Richard Kamwi, a former health minister, said he backed the refusal. "The time has come that we should own Africa," he said. "The responsibility of data belongs to Namibia and should be used in the interest of Namibia and not of other countries." He added: "No one has the right to get a sovereign state to be used for other things."
That convergence matters politically. President Netumbo Nandi-Ndaitwah's government has been arguing since the 2025 aid disruptions that Namibia has the internal capacity to sustain its health programs. Refusing American terms is a test of that claim, and a cross-party consensus makes it harder for Washington to characterize the objection as partisan posturing.
Why this is bigger than one bilateral
The health ministry has raised a further concern that reaches well beyond Namibia's borders: a bilateral agreement of this kind risks undermining Namibia's position in the ongoing negotiations over the Pathogen Access and Benefit-Sharing system under the WHO pandemic agreement, and conflicts with a commitment to advance Africa's regional position.
This is the sharpest argument in the file. PABS is being negotiated precisely to establish that sharing pathogens must come with guaranteed access to the vaccines and treatments derived from them. Every bilateral deal that trades samples and data for money without such guarantees weakens the multilateral bargaining position of the entire African bloc. A country that signs individually may improve its own cash position while degrading the leverage of the group — the classic collective-action failure, applied to genomic material.
What to watch
The immediate deadline is the U.S. appropriation at the end of October. Between now and then, three questions will resolve.
Whether Washington splits the difference. It already dropped the specimen component in November 2025. If it concedes further on data scope, auditability and duration, an agreement is reachable — and would establish a template other reluctant governments could invoke.
Whether Namibia's contingency funding is real. Officials say alternatives have been "actively explored." Naming those sources — domestic budget reallocation, the Global Fund, regional mechanisms — would convert a principled position into a credible one.
Whether the refusals cohere. Ghana, South Africa, Zambia, Zimbabwe and now Namibia have each declined separately. Analysts have argued that African bargaining power over data depends on collective negotiation rather than country-by-country resistance. Whether the African Union or the Africa CDC turns five parallel refusals into one negotiating position is the question that will determine whether this week's stand in Windhoek is a precedent or an outlier.
